cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc26gdwz
title: CCDC 2039641: Experimental Crystal Structure Determination

description: Related Article: Xin-Ting Liang, Bao-Chuan Sun, Chang Liu, Yuan-He Li, Nan Zhang, Qian-Qian Xu, Zhong-Chao Zhang, Yi-Xin Han, Jia-Hua Chen, Zhen Yang|2021|J.Org.Chem.|86|2135|doi:10.1021/acs.joc.0c02494
DOI: 10.5517/ccdc.csd.cc26j643
title: CCDC 2041354: Experimental Crystal Structure Determination

description: Related Article: Yifan Deng, Chia-Ping H. Yang, Amos B. Smith III|2021|J.Am.Chem.Soc.|143|1740|doi:10.1021/jacs.0c11424
DOI: 10.5063/z31x15
title: AgEvidence: Agro-environmental responses of conservation agricultural practices in the US Midwest published from 1980 to 2020

description: AgEvidence is a database of the multiple benefits and trade-offs associated with conservation agricultural practices in the United States Midwest. The purpose of these data are to provide organizations, policy makers, scientists, and other interested parties with all the available evidence related to the diversity and magnitude of agro-environmental impacts that occur following the implementation of conservation practices. The conservation practices we focused on include winter cover crops, conservation tillage, strategic nutrient management, and early season pest management in corn and soybean systems. Data were extracted from peer-reviewed literature published between 1980 and 2020 with experimental field sites located in at least one of the following states: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, North Dakota, Nebraska, Ohio, South Dakota, and Wisconsin. Our dataset includes all response variables reported in each paper where there are isolated comparisons of a conservation practice (e.g. soil nitrate content following winter fallow and following winter cover crop). With this approach, we were able to capture the state-of-knowledge for a wide diversity of response variables and identify where we lack knowledge.
DOI: 10.5281/zenodo.4536062
title: Dataset related to article "Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters"

description: This record contains raw data related to article “Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters" Abstract We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. This analysis is embedded into a larger prospective study (NCT03563482). Twelve out of 20 patients received nivolumab, one patient received combination of nivolumab and ipilimumab, whereas the others received pembrolizumab. Median sPD-L1 level at baseline was 27.22 pg/mL. We found a significant association between patients with elevated sPD-L1, above the median value, and high metabolic tumor burden, expressed by metabolic tumor volume (MTV, 115.3 vs. 35.5, <em>p</em> = 0.034) and total lesion glycolysis (TLG, 687 vs. 210.1, <em>p</em> = 0.049). At the first restaging after 7-8 weeks, median sPD-L1 levels significantly increased as compared to baseline median value (43.9 pg/mL, <em>p</em> = 0.017). No significant differences in response rates were detected, according to both morphological and metabolic response criteria. Likewise, no difference in survival outcomes were observed between low sPD-L1 and high sPD-L1 patients. The increase of sPD-L1 concentrations during ICI treatment may reflect the expansion of tumor volume and the tumor lysis. Moreover, it is supposed that sPD-L1 has its own biological action, either by reducing membrane PD-1 sites available for nivolumab or by inducing lymphocytes exhaustion after binding their membrane PD-1. Further, larger studies are needed to confirm our preliminary results on the role of sPD-L1 during ICI therapy.
DOI: 10.5281/zenodo.4536061
title: Dataset related to article "Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters"

description: This record contains raw data related to article “Soluble PD-L1 in NSCLC Patients Treated With Checkpoint Inhibitors and Its Correlation With Metabolic Parameters" Abstract We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT). Between July 2017 and May 2019, we enrolled 20 candidate patients of ICI therapy who had serum frozen samples and 18F-FDG PET/CT available, both at baseline and at the first response evaluation. This analysis is embedded into a larger prospective study (NCT03563482). Twelve out of 20 patients received nivolumab, one patient received combination of nivolumab and ipilimumab, whereas the others received pembrolizumab. Median sPD-L1 level at baseline was 27.22 pg/mL. We found a significant association between patients with elevated sPD-L1, above the median value, and high metabolic tumor burden, expressed by metabolic tumor volume (MTV, 115.3 vs. 35.5, <em>p</em> = 0.034) and total lesion glycolysis (TLG, 687 vs. 210.1, <em>p</em> = 0.049). At the first restaging after 7-8 weeks, median sPD-L1 levels significantly increased as compared to baseline median value (43.9 pg/mL, <em>p</em> = 0.017). No significant differences in response rates were detected, according to both morphological and metabolic response criteria. Likewise, no difference in survival outcomes were observed between low sPD-L1 and high sPD-L1 patients. The increase of sPD-L1 concentrations during ICI treatment may reflect the expansion of tumor volume and the tumor lysis. Moreover, it is supposed that sPD-L1 has its own biological action, either by reducing membrane PD-1 sites available for nivolumab or by inducing lymphocytes exhaustion after binding their membrane PD-1. Further, larger studies are needed to confirm our preliminary results on the role of sPD-L1 during ICI therapy.
DOI: 10.5281/zenodo.4088142
title: Genomics of resistance in Norway spruce to Heterobasidion annosum s.s.and Heterobasidion parviporum

description: Filtered variants and resistance traits to Heterobasidion annosum s.s. and Heterobasidion parviporum datasets for GWAS in Norway spruce
DOI: 10.5281/zenodo.4088141
title: Genomics of resistance in Norway spruce to Heterobasidion annosum s.s.and Heterobasidion parviporum

description: Filtered variants and resistance traits to Heterobasidion annosum s.s. and Heterobasidion parviporum datasets for GWAS in Norway spruce
DOI: 10.15468/vh8e2a
title: A new species of the genus Lasioseius (Acari: Blattisociidae) inhabiting litter of secondary rainforest in Sumatra, Indonesia

description: This dataset contains the digitized treatments in Plazi based on the original journal article Quintero-Gutiérrez, Edwin Javier, Sandmann, Dorothee, Cómbita-Heredia, Orlando, Klarner, Bernhard, Widyastuti, Rahayu, Scheu, Stefan (2020): A new species of the genus Lasioseius (Acari: Blattisociidae) inhabiting litter of secondary rainforest in Sumatra, Indonesia. Acarologia 60 (2): 338-352, DOI: 10.24349/acarologia/20204371
DOI: 10.5281/zenodo.4536165
title: Data for Developmental cell programs are co-opted in inflammatory skin disease - filtered, annotated anndata object

description: Dataset to accompany BioRxiv preprint "Poised cell circuits in human skin are activated in disease" (https://www.biorxiv.org/content/10.1101/2020.11.05.369363v1). Data in AnnData (h5ad) format. Preprocessed to exclude doublets and low quality cells (&lt;200 genes and &gt;20% mitochondrial content). Includes neighborhood graph and UMAP coordinates and annotation from the manuscript in metadata. Full dataset with annotation ("combined") in obs.
description: This has been updated - the previous version had multiple old annotations that are no longer in use,
DOI: 10.21227/0ft4-d597
title: Lumos5G Dataset

description: The emerging 5G services offer numerous new opportunities for networked applications. In this study, we seek to answer two key questions: i) is the throughput of mmWave 5G predictable, and ii) can we build "good" machine learning models for 5G throughput prediction? To this end, we conduct a measurement study of commercial mmWave 5G services in a major U.S. city, focusing on the throughput as perceived by applications running on user equipment (UE). Through extensive experiments and statistical analysis, we identify key UE-side factors that affect 5G performance and quantify to what extent the 5G throughput can be predicted. We then propose Lumos5G - a composable machine learning (ML) framework that judiciously considers features and their combinations, and apply state-of-the-art ML techniques for making context-aware 5G throughput predictions. We demonstrate that our framework is able to achieve 1.37x to 4.84x reduction in prediction error compared to existing models. Our work can be viewed as a feasibility study for building what we envisage as a dynamic 5G throughput map (akin to Google traffic map). We believe this approach provides opportunities and challenges in building future 5G-aware apps.
DOI: 10.5281/zenodo.4536169
title: Dataset related to article "Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT"

description: This record contains raw data related to article “Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of <sup>18</sup> F-FDG PET/CT" Abstract A new pattern of response, so-called hyperprogressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICIs). Our aim was to investigate the prevalence of such a phenomenon and to assess its association with clinical variables and metabolic parameters by <sup>18</sup>F-FDG PET/CT. <strong>Methods:</strong> Data from 50 patients (34 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were prospectively collected. All patients underwent contrast-enhanced CT, <sup>18</sup>F-FDG PET/CT, and complete peripheral blood sampling at baseline before ICI treatment. HPD was defined according to clinical and radiologic criteria. Because of rapid disease progression or worsening of clinical condition, radiologic response assessment was available for only 46 of the 50 patients. Overall survival (OS) was analyzed using the Kaplan-Meier method and the log-rank test. A Cox proportional hazards regression analysis was used to evaluate factors independently associated with OS. Median follow-up was 12.4 mo (range, 9.7-15.2 mo). <strong>Results:</strong> We identified the following response categories: 10 cases as complete or partial response, 17 cases as stable disease, 5 cases as progressive disease, and 14 cases as HPD. Among metabolic parameters, we observed a statistically significant association between HPD status and tumor burden, expressed by both TLG (756.1 cm<sup>3</sup> for HPD vs. 475.6 cm<sup>3</sup> for non-HPD, <em>P</em> = 0.042) and MTV (287.3 for HPD vs. 62.1 for non-HPD, <em>P</em> = 0.011). Among clinical variables, 12 of 14 patients (85.7%) within the HPD group, compared with 8 of 32 patients (25%) in the non-HPD group, had more than 2 metastatic sites (<em>P</em> &lt; 0.001). In addition, the derived neutrophil-to-lymphocyte ratio and platelet count were significantly associated with HPD status (<em>P</em> = 0.038 and <em>P</em> = 0.025, respectively). Survival analysis showed a median OS of 4 mo for the HPD group, compared with 15 mo for the non-HPD group (<em>P</em> = 0.003). Likewise, median OS was significantly different when we considered all the response categories: complete or partial response, stable disease, progressive disease, and HPD (<em>P</em> = 0.001). Finally, multivariate analysis identified metabolic tumor volume and derived neutrophil-to-lymphocyte ratio as independent predictors for OS. <strong>Conclusion:</strong> Our results suggest that the use of ICIs might represent a concern in patients with high metabolic tumor burden and inflammatory indices at baseline. However, additional studies are needed.
DOI: 10.5281/zenodo.4536168
title: Dataset related to article "Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT"

description: This record contains raw data related to article “Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of <sup>18</sup> F-FDG PET/CT" Abstract A new pattern of response, so-called hyperprogressive disease (HPD), is emerging during treatment with immune checkpoint inhibitors (ICIs). Our aim was to investigate the prevalence of such a phenomenon and to assess its association with clinical variables and metabolic parameters by <sup>18</sup>F-FDG PET/CT. <strong>Methods:</strong> Data from 50 patients (34 men and 16 women; median age, 73 y) with non-small cell lung carcinoma treated with ICIs were prospectively collected. All patients underwent contrast-enhanced CT, <sup>18</sup>F-FDG PET/CT, and complete peripheral blood sampling at baseline before ICI treatment. HPD was defined according to clinical and radiologic criteria. Because of rapid disease progression or worsening of clinical condition, radiologic response assessment was available for only 46 of the 50 patients. Overall survival (OS) was analyzed using the Kaplan-Meier method and the log-rank test. A Cox proportional hazards regression analysis was used to evaluate factors independently associated with OS. Median follow-up was 12.4 mo (range, 9.7-15.2 mo). <strong>Results:</strong> We identified the following response categories: 10 cases as complete or partial response, 17 cases as stable disease, 5 cases as progressive disease, and 14 cases as HPD. Among metabolic parameters, we observed a statistically significant association between HPD status and tumor burden, expressed by both TLG (756.1 cm<sup>3</sup> for HPD vs. 475.6 cm<sup>3</sup> for non-HPD, <em>P</em> = 0.042) and MTV (287.3 for HPD vs. 62.1 for non-HPD, <em>P</em> = 0.011). Among clinical variables, 12 of 14 patients (85.7%) within the HPD group, compared with 8 of 32 patients (25%) in the non-HPD group, had more than 2 metastatic sites (<em>P</em> &lt; 0.001). In addition, the derived neutrophil-to-lymphocyte ratio and platelet count were significantly associated with HPD status (<em>P</em> = 0.038 and <em>P</em> = 0.025, respectively). Survival analysis showed a median OS of 4 mo for the HPD group, compared with 15 mo for the non-HPD group (<em>P</em> = 0.003). Likewise, median OS was significantly different when we considered all the response categories: complete or partial response, stable disease, progressive disease, and HPD (<em>P</em> = 0.001). Finally, multivariate analysis identified metabolic tumor volume and derived neutrophil-to-lymphocyte ratio as independent predictors for OS. <strong>Conclusion:</strong> Our results suggest that the use of ICIs might represent a concern in patients with high metabolic tumor burden and inflammatory indices at baseline. However, additional studies are needed.
DOI: 10.6084/m9.figshare.13913024.v1
title: Data and R script for De Vries et al. 2021

description: Data files and R scripts as used in De Vries et al. 2021. All details on sampling, experimental set up, laboratory analyses, and data analyses are described in this paper. Please see the Read_me_Data_glacier_all file for explanations about variables and metadata.
DOI: 10.15468/xrc89c
title: Contribution to the knowledge of oribatid mites of the genus Austrocarabodes (Acari, Oribatida, Carabodidae) of Madagascar

description: This dataset contains the digitized treatments in Plazi based on the original journal article Ermilov, Sergey G., Starý, Josef (2020): Contribution to the knowledge of oribatid mites of the genus Austrocarabodes (Acari, Oribatida, Carabodidae) of Madagascar. Acarologia 60 (2): 353-370, DOI: 10.24349/acarologia/20204373
DOI: 10.15468/dfhnq3
title: New records of the water mite genus Arrenurus Dugès, 1834 from South America (Acari: Hydrachnidia: Arrenuridae), with the description of five new species and one new subspecies

description: This dataset contains the digitized treatments in Plazi based on the original journal article Smit, Harry (2020): New records of the water mite genus Arrenurus Dugès, 1834 from South America (Acari: Hydrachnidia: Arrenuridae), with the description of five new species and one new subspecies. Acarologia 60 (2): 371-389, DOI: 10.24349/acarologia/20204374
DOI: 10.5281/zenodo.4536212
title: Dataset related to article "Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1"

description: This record contains raw data related to article "Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1" Abstract <strong>Introduction/Aim:</strong> Immunotherapy with immune checkpoint inhibitors (ICIs) has positively changed the history of several malignant tumors. In parallel, new challenges have emerged in the evaluation of treatment response as a result of their peculiar anticancer effect. In the current study, we aimed to compare different response criteria, both morphological and metabolic, for assessing response and outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with ICI. <strong>Materials and Methods:</strong> Overall, 52 patients with advanced NSCLC candidate to ICI were prospectively evaluated. Inclusion criteria comprised whole-body contrast-enhanced CT and <sup>18</sup>F-FDG PET/CT at baseline and at the first response evaluation 3 or 4 cycles after ICI. Response assessment on CT was performed according to RECIST 1.1 and imRECIST criteria, whereas metabolic response on PET was computed by EORTC, PERCIST, imPERCIST, and PERCIMT criteria. The concordance between the different tumor response criteria and the performance of each criterion to predict progression-free survival (PFS) and overall survival (OS) were calculated. <strong>Results:</strong> Inclusion criteria were fulfilled in 35 out of 52 patients. We observed a low agreement between imRECIST and imPERCIST (κ = 0.143) with discordant response in 20 patients, particularly regarding stable disease and progressive disease groups. Fair agreement between imRECIST and EORTC (κ = 0.340), and PERCIST (κ = 0.342), and moderate for PERCIMT (κ = 0.413) were detected. All criteria were significantly associated with PFS, while only PERCIMT and imPERCIST were associated with OS. Of note, in patients classified as immune stable disease (iSD), imPERCIST, and PERCIMT well-differentiated those with longer PFS (<em>p</em> &lt; 0.001, <em>p</em> = 0.009) and OS (<em>p</em> = 0.001, <em>p</em> = 0.002). In the multivariate analysis, performance status [hazard ratio (HR) = 0.278, <em>p</em> = 0.015], imRECIST (HR = 3.799, <em>p</em> = 0.026), and imPERCIST (HR = 4.064, <em>p</em> = 0.014) were predictive factors for PFS, while only performance status (HR = 0.327, <em>p</em> = 0.035) and imPERCIST (HR = 3.247, <em>p</em> = 0.007) were predictive for OS. <strong>Conclusions:</strong> At the first evaluation during treatment with ICI, imPERCIST criteria correctly evaluated treatment response and appeared able to predict survival. Moreover, in patients with iSD on CT, imPERCIST were able to discriminate those with longer survival. This advantage might allow for earlier therapy modification based on metabolic response
DOI: 10.5281/zenodo.4536211
title: Dataset related to article "Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1"

description: This record contains raw data related to article "Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1" Abstract <strong>Introduction/Aim:</strong> Immunotherapy with immune checkpoint inhibitors (ICIs) has positively changed the history of several malignant tumors. In parallel, new challenges have emerged in the evaluation of treatment response as a result of their peculiar anticancer effect. In the current study, we aimed to compare different response criteria, both morphological and metabolic, for assessing response and outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with ICI. <strong>Materials and Methods:</strong> Overall, 52 patients with advanced NSCLC candidate to ICI were prospectively evaluated. Inclusion criteria comprised whole-body contrast-enhanced CT and <sup>18</sup>F-FDG PET/CT at baseline and at the first response evaluation 3 or 4 cycles after ICI. Response assessment on CT was performed according to RECIST 1.1 and imRECIST criteria, whereas metabolic response on PET was computed by EORTC, PERCIST, imPERCIST, and PERCIMT criteria. The concordance between the different tumor response criteria and the performance of each criterion to predict progression-free survival (PFS) and overall survival (OS) were calculated. <strong>Results:</strong> Inclusion criteria were fulfilled in 35 out of 52 patients. We observed a low agreement between imRECIST and imPERCIST (κ = 0.143) with discordant response in 20 patients, particularly regarding stable disease and progressive disease groups. Fair agreement between imRECIST and EORTC (κ = 0.340), and PERCIST (κ = 0.342), and moderate for PERCIMT (κ = 0.413) were detected. All criteria were significantly associated with PFS, while only PERCIMT and imPERCIST were associated with OS. Of note, in patients classified as immune stable disease (iSD), imPERCIST, and PERCIMT well-differentiated those with longer PFS (<em>p</em> &lt; 0.001, <em>p</em> = 0.009) and OS (<em>p</em> = 0.001, <em>p</em> = 0.002). In the multivariate analysis, performance status [hazard ratio (HR) = 0.278, <em>p</em> = 0.015], imRECIST (HR = 3.799, <em>p</em> = 0.026), and imPERCIST (HR = 4.064, <em>p</em> = 0.014) were predictive factors for PFS, while only performance status (HR = 0.327, <em>p</em> = 0.035) and imPERCIST (HR = 3.247, <em>p</em> = 0.007) were predictive for OS. <strong>Conclusions:</strong> At the first evaluation during treatment with ICI, imPERCIST criteria correctly evaluated treatment response and appeared able to predict survival. Moreover, in patients with iSD on CT, imPERCIST were able to discriminate those with longer survival. This advantage might allow for earlier therapy modification based on metabolic response